News
The Multiple Myeloma Pipeline: Therapies to Watch
New investigational therapies in the pipeline that address multiple myelomainclude both small-molecule and immunotherapeutic approaches — and in...
Emerging Approaches Offer Hope in Heavily Pretreated Myeloma
When patients with multiple myeloma become refractory to lenalidomide (Revlimid) or bortezomib (Velcade), or have penta-refractory disease, there...
CAR T-cell therapy: What you need to know
Chimeric antigen receptor T-cell therapy, also known as CAR T-cell therapy, is approved for two indications — relapsed or refractory large B-cell...
Patient Seminar: From 45 South – The Otago Myeloma Research Trust
INVITATION Patient Seminar: From 45 South - The Otago Myeloma Research Trust Presented by Dr Ian Morrison on 1 August, 5.30 at BNZ Partners Centre,...
Dr. Lesokhin Discusses Exciting Advances in Multiple Myeloma
Alexander M. Lesokhin, MD, assistant attending, Department of Medicine and Myeloma Service, Memorial Sloan Kettering Cancer Center, discusses some...
Stand Up To Cancer dream team strives to revolutionize myeloma treatment
Stand Up To Cancer awarded a $10 million grant to a research “dream team” that will strive to revolutionize the treatment of multiple myeloma...
Current Developments in Immunotherapy in the Treatment of Multiple Myeloma
Multiple myeloma (MM) is the second most common hematologic malignancy and represents approximately 10% of all hematological neoplasms. Standard...
Newsletter: June 2018
Greetings as the days get shorter. Thanks to all the people who turned out for our last Wellington seminar on February 21. Dr Rob Weinkove delivered...
Companies Collaborating to Use ClonoSEQ Assay in Multiple Myeloma Trials Testing Isatuximab
Adaptive Biotechnologies is collaborating with Sanofi to use its clonoSEQ Assay for measuring minimal residual disease in multiple myeloma patients...
Elotuzumab/Pomalidomide Prolongs PFS in Pretreated Multiple Myeloma
The addition of elotuzumab (Empliciti) to pomalidomide (Pomalyst) and dexamethasone cut the risk of disease progression or death by 46% compared...
Once weekly versus twice weekly carfilzomib dosing in patients with relapsed and refractory multiple myeloma
Once weekly versus twice weekly carfilzomib dosing in patients with relapsed and refractory multiple myeloma (A.R.R.O.W.): interim analysis results...
Early Results Suggest That Once-Weekly, High-Dose Carfilzomib Prolongs PFS in Multiple Myeloma
Administering carfilzomib once a week significantly improves progression-free survival (PFS) and toxicity compared with twice a week among patients...